It seems the market has decided that the maiden JORC coming in dramatically above expectations is a bad thing. Down nearly 10% since the ANN, and sell side has bloated. As the Yanks say, 'go figure'.
PTX This rare type of lymphoma ruins the body – so do existing treatments. Prescient could have a solution
